Research · Sep 3, 2026
[TMDX] TransMedics Thesis 2026: OCS Penetration + Donor Pool Expansion Drive Profitable Growth
TransMedics FY2025 revenue ~$455M (+32% YoY); adj. operating income ~$80M as company crossed sustained profitability inflection. OCS device + disposables (~$240M, ~50%) plus National OCS Program logistics (~$220M, ~48%) — NOP scaling 50%+ on in-house Summit Aviation acquisition (FY2024). OCS penetration of US transplants ~23% blended (Heart 22%, Liver 22%, Lung 26%) — substantial penetration runway remains. FY2026 thesis: continued DCD donor pool expansion drives both penetration AND absolute US transplant volume growth (US liver transplants grew from ~9,200 FY2020 to ~10,000+ FY2024); NOP economics improving as owned aviation replaces third-party charters; key risks: SEC short-seller allegations + DOJ investigation overhang, international expansion execution.